DBVT DBV Technologies S.A. American Depositary Shares

XNAS 9.98 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

DBVT $9.98 —
Key stats
$9.98
52-Week Range
$8.63 – $26.18
YTD
-47.61%
IV Rank (30D)
27.35
Straddle Price
$3.27
P/C Vol Ratio
0.03
Market Cap
$0.6B
Open
$10.11
Day Range
$9.89 – $10.14
Volume
214,829
Prev Close
$9.75
Fair Value
MODEL: NEUTRAL

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY0.44
Cost of Equity (CAPM)7.17% (VRP-adj)
WACC7.30%
Volatility Risk Premium+108.3pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.2B
Return on Equity (TTM)-109.7%
Book / Price5.6%
Gross Margin (TTM)100.0%
FCF Margin (TTM)-3399.0%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$11.88 (Market Anchor value)
SMA 20 / Bollinger Mid$9.89
Bollinger Width / SMA20333.2% (drives anchor stability)
Net Debt$-0.2B
Market Cap$3B
Peers used for multiples: ABVX, BBVA, CMPS, GSK, NVO, NVS, TAK, TEVA
60-Day Conviction
1%
20-Day Fair Value
≈ by Nov 25, 2026
$9.99
α +0.1% rank 56%
conviction
5%
40-Day Fair Value
≈ by Dec 24, 2026
$9.99
α +0.1% rank 62%
conviction
3%
60-Day Fair Value
≈ by Jan 22, 2027
$9.98
α +0.0% rank 55%
conviction
1%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $3.34 20% median 5.9× · 3 peers
Peer P/S n/a 0%
Market Anchor (SMA50) $11.88 80% stability 78% (BB-width)
Options Expected (B-L 30d) $9.63 0% 5 strikes · skew +0.26
As of 2026-10-27 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.6B
Employees
170
List Date
2014-10-22
CIK
0001613780
Next Earnings
2026-10-27
EPS Forecast
($0.60) (1 est.)
Headquarters
Chatillon, I0
Homepage
https://www.dbv-technologies.com

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan86.91%-13.56%-12.00%-3.20%30.00%13.44%16.93%
Feb-2.90%-15.19%5.84%-7.87%9.61%-2.78%-2.21%
Mar-2.38%20.45%16.55%-9.75%72.22%-10.15%14.49%
Apr22.74%-18.87%-12.87%-15.18%39.47%2.44%2.95%
May-4.88%9.03%30.00%-18.84%-3.02%-3.88%1.40%
Jun-5.37%65.58%-3.06%-32.12%18.34%-12.77%5.10%
Jul-8.61%6.69%-21.07%18.39%-18.88%-14.72%-6.37%
Aug10.24%-19.92%-1.86%-5.26%7.22%1.77%-1.30%
Sep-12.50%-8.29%-13.38%-19.54%8.93%-12.37%-9.53%
Oct-36.61%-14.61%-24.06%6.63%45.38%-10.97%*-5.71%
Nov-7.69%-14.01%-27.45%2.47%-8.14%---10.96%
Dec-44.25%10.07%28.24%-22.17%47.69%--3.92%
Total-43.71%-18.10%-43.49%-71.14%634.02%-42.37%69.20%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $9.89
SMA 50: $11.88
SMA 200: $17.10
Current: $9.98
EMA 12: $9.70
EMA 26: $10.35
MACD: -0.6531 | Signal: 0.1733
BEARISH
ADX (14): 34.12
TREND
+DI: 22.38
−DI: 27.08

Momentum Oscillators

RSI (14): 43.68
NEUTRAL
Stoch %K: 64.78
Stoch %D: 51.23
Williams %R: -10.60

Volume & Volatility

BB Upper: $11.51
BB Lower: $8.26
NEUTRAL
OBV: 27,438,638
Vol SMA 20: 430,020
Vol ROC: -31.10%
ATR: $0.50
True Range: $0.39
HV 20: 48.6%
HV 30: 50.7%
HV 60: 51.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

Here is my response to the prompt:

LLM Stock Analysis Report for DBVT

Executive Summary

  • Overall Assessment: NEUTRAL (confidence level: 6/10)
  • Key Drivers and Primary Risks: Recent news sentiment aligns with technical signals, with positive news driving short-term momentum. However, high volatility and beta >1.0 indicate potential risk.
  • 2-3 Sentence Investment Thesis: DBVT's recent price movement is driven by a mix of positive news and market dynamics. While the stock shows promise in the short term, investors should be cautious due to above-average volatility and beta.
  • Recent News Sentiment Impact: Recent headlines are generally positive, with news articles highlighting company announcements and milestones.

Technical Analysis

  • Trend Direction: Short-term (1-4 weeks): Bullish; Medium-term (1-3 months): Neutral; Long-term (3-12 months): Bearish
  • Support/Resistance Levels: Key levels to watch are $14.98 (upper Bollinger Band), $14.19 (SMA 20), and $13.39 (lower Bollinger Band).
  • Momentum Signals:
    • RSI interpretation: Neutral (42.72)
    • MACD signal: Bearish (histogram -0.17)
    • Bollinger Bands position: Squeeze
  • Volume Analysis: Volume trends indicate caution, with volume rate of change -15.06% and on-balance volume declining.

News & Sentiment Analysis

  • Recent Headlines Summary: Recent news articles highlight company announcements and milestones, driving positive sentiment.
  • Sentiment Assessment: Overall sentiment is NEUTRAL, with 3/5 articles having a positive tone.
  • Catalyst Identification: Upcoming events include the BLA submission update for the VIASKIN Peanut Patch in Children Aged 4 through 7 Years.
  • Market Narrative: Recent news aligns with technical signals, driving short-term momentum.

Risk & Volatility Assessment

  • Beta Interpretation: Beta >1.0 indicates high risk relative to market.
  • Volatility Regime: Current volatility is above historical levels (HV20 49.9%, HV30 45.4%).
  • Options Market Signals: IV rank is low (8.0%), suggesting historically low volatility; put/call ratios indicate bearish sentiment.

Market Context & Positioning

  • Sector Performance: DBVT's sector performance is mixed, with no clear trend.
  • Institutional Activity: Institutional interest is moderate, with 1 call vs 81 puts in options activity.
  • Correlation Analysis: DBVT moves with market amplification (correlation: 0.17).
  • Relative Valuation: Position within trading range.

Key Levels & Action Items

  • Critical Price Levels: Support at $14.19 (SMA 20) and resistance at $14.98 (upper Bollinger Band).
  • Breakout/Breakdown Levels: Breakout above $15.00 or breakdown below $13.50 could trigger significant moves.
  • Time-Sensitive Catalysts: BLA submission update for the VIASKIN Peanut Patch in Children Aged 4 through 7 Years is a key event to watch.
  • Risk Management: Stop-loss levels should be set at $12.50, with position sizing considerations.

This comprehensive analysis assesses DBVT's current market situation, highlighting both bullish and bearish signals. The recent news sentiment aligns with technical indicators, driving short-term momentum. However, high volatility and beta >1.0 indicate potential risk. As a result, investors should exercise caution when considering a trade.

Generated
News
All DBVT news →
Showing 1–10 of 50
Page 1 of 5
Earnings History
5 of 6 under expected move
Avg Expected Move
213.41%
Avg Actual Move
3.31%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-05-03 unknown 2.60% 5.85% 2.25x Exceeded
2023-10-31 After-Close 135.65% 0.99% 0.01x Within
2024-03-07 After-Close 194.90% 3.87% 0.02x Within
2024-07-30 unknown 258.68% 2.32% 0.01x Within
2024-10-22 unknown 360.71% 2.84% 0.01x Within
2024-11-06 unknown 327.92% 4.00% 0.01x Within

Earnings calendar: this week’s reports with expected vs actual moves →

DBVT Options Activity & IV Rank

DBVT IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 100.2%
7-DTE IV: —
Expected Move: $3.27
7-DTE Move: $3.27
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 293
Put Volume: 8
P/C Volume: 0.027
BULLISH
Call OI: 289
Put OI: 8
P/C OI: 0.028
Total OI: 297

ATM Options Pricing

ATM Call: $2.50
ATM Put: $0.78
Call %: 25.1%
Put %: 7.8%

Chain Summary

Chain Volume: 466
Chain OI: 484
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 74.8% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)27.4MediumOct 26
Straddle Price (30 DTE)$3.27Oct 26
Beta Analysis

Risk Metrics

Beta: 0.7876
Alpha: -30.31%
Correlation: 0.1433
R-Squared: 2.1%
Stock Volatility: 70.1%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own DBVT
5 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Duquesne Family Office Family office
Stanley Druckenmiller
$6.3M
0.14%
#76 of 860.0%13F
Millennium Management Hedge fund
Izzy Englander
$4.4M
0.00%
#2127 of 3716-16.0%13F
Citadel Hedge fund
Ken Griffin
$374K
0.00%
#4818 of 6285new13F
Point72 Hedge fund
Steve Cohen
$199K
0.00%
#1785 of 1945new13F
Rockefeller Capital Management Family office
Rockefeller family
$20K
0.00%
#3725 of 4729new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

DBVT Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 284,556,136 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

72 filers21,319,208 shares$342.65M value7.49% of float
# Filer Shares Value % of Total % of Float Period
1 MPM BioImpact LLC 3,666,284 $60.13M 17.55% 1.29% 2026-06-30
2 Siren, L.L.C. 1,857,362 $30.46M 8.89% 0.65% 2026-06-30
3 Vivo Capital, LLC 1,844,758 $30.25M 8.83% 0.65% 2026-06-30
4 PERCEPTIVE ADVISORS LLC 1,653,350 $27.11M 7.91% 0.58% 2026-06-30
5 BAKER BROS. ADVISORS LP 1,461,425 $23.97M 6.99% 0.51% 2026-06-30
6 Artisan Partners Limited Partnership 1,372,851 $22.51M 6.57% 0.48% 2026-06-30
7 UBS Group AG Custodian 1,313,439 $21.54M 6.29% 0.46% 2026-06-30
8 Morgan Stanley Custodian 954,908 $15.66M 4.57% 0.34% 2026-06-30
9 Logos Global Management LP 915,000 $15.01M 4.38% 0.32% 2026-06-30
10 Patient Square Capital LP 909,474 $14.92M 4.35% 0.32% 2026-06-30
11 Octagon Capital Advisors LP 574,200 $9.42M 2.75% 0.20% 2026-06-30
12 ADAR1 Capital Management, LLC 528,295 $8.66M 2.53% 0.19% 2026-06-30
13 Redmile Group, LLC 410,440 $6.73M 1.96% 0.14% 2026-06-30
14 Duquesne Family Office LLC 383,363 $6.29M 1.83% 0.13% 2026-06-30
15 Ameriprise Financial, Inc. Custodian 378,497 $6.21M 1.81% 0.13% 2026-06-30
16 Millennium Management LLC Custodian 267,783 $4.39M 1.28% 0.09% 2026-06-30
17 Elmind Capital, LP 265,000 $4.35M 1.27% 0.09% 2026-06-30
18 Jane Street Group, LLC Custodian 223,915 $3.67M 1.07% 0.08% 2026-06-30
19 Ishara Investments LP 184,500 $3.03M 0.88% 0.06% 2026-06-30
20 Yiheng Capital Management, L.P. 170,142 $2.79M 0.81% 0.06% 2026-06-30
21 BOOTHBAY FUND MANAGEMENT, LLC 163,401 $2.68M 0.78% 0.06% 2026-06-30
22 GREAT POINT PARTNERS LLC 156,906 $2.57M 0.75% 0.06% 2026-06-30
23 HRT FINANCIAL LP 151,197 $2.48M 0.72% 0.05% 2026-06-30
24 NEW YORK STATE COMMON RETIREMENT FUND 119,335 $1.96M 0.57% 0.04% 2026-06-30
25 Envestnet Asset Management, Inc. 113,823 $1.87M 0.54% 0.04% 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

DBVT Insider Trading (Form 4)

Latest: 2026-07-31
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-07-31 Pharis Mohideen Chief Medical Officer Sell (S) −464 $2.70 -$1.3K EDGAR
2026-02-02 Pharis Mohideen Chief Medical Officer Sell (S) −534 $4.86 -$2.6K EDGAR
2026-01-14 667, L.P. Director Exer (M) — — EDGAR
2025-12-19 SA Bpifrance Sell (S) −16,845,465 $4.60 -$77.42M EDGAR
2025-11-25 Pharis Mohideen Chief Medical Officer Mixed +35,880 $2.86 -$23.2K EDGAR
2025-11-24 Virginie Boucinha Chief Financial Officer Award (A) +32,000 — EDGAR
2025-11-24 Daniel Tasse CHIEF EXECUTIVE OFFICER Grant (A) +964,000 opt — EDGAR
2025-11-24 Kevin Michael Trapp Chief Commercial Officer Award (A) +55,000 — EDGAR
2025-07-31 Pharis Mohideen Chief Medical Officer Sell (S) −464 $2.22 -$1.0K EDGAR
2025-05-27 Pharis Mohideen Chief Medical Officer Sell (S) −397 $1.84 -$730 EDGAR
2025-03-31 Felix Baker Director Grant (A) +327,658,752 RSU — EDGAR
2025-01-31 Pharis Mohideen Chief Medical Officer Sell (S) −600 $0.85 -$510 EDGAR
2024-12-05 Daniel Tasse CHIEF EXECUTIVE OFFICER Grant (A) +813,200 opt — EDGAR
2024-11-27 Pharis Mohideen Chief Medical Officer Sell (S) −907 $0.55 -$503 EDGAR
2024-11-25 Pharis Mohideen Chief Medical Officer Mixed +32,650 $0.54 -$1.3K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

DBVT Insider Holdings

5 insiders · @ $9.98
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 SA Bpifrance 226,133 $2.26M -$77.42M 1 2025-12-19
2 Pharis Mohideen Chief Medical Officer 144,531 $1.44M -$45.0K 14 2026-07-31
3 Virginie Boucinha Chief Financial Officer 70,000 $698.6K $0 3 2025-11-24
4 Kevin Michael Trapp Chief Commercial Officer 55,000 $548.9K $0 1 2025-11-24
5 Daniel Tasse CHIEF EXECUTIVE OFFICER 1,709 $17.1K $14.2K 6 2025-11-24
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
2 ETFs hold DBVT
2 shown · $776.91K total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 AADR AdvisorShares Dorsey Wright ADR ETF Nport 1.72% $716,073 — 2026-06-30
2 APIE ActivePassive International Equity ETF Nport 0.01% $60,836 — 2026-08-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.70
TTM Revenue
$5.02M
TTM Net Income
$-175.99M
TTM Op. Cash Flow
$-169.31M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$700.00K$-50.40M$-0.12$-52.60M
Q1 '262026-03-31$900.00K$-47.60M$-0.11$-49.10M
Q4 '252025-12-31$645.00K$-44.83M$-0.23$-35.17M
Q3 '252025-09-30$2.77M$-33.16M$-0.24$-32.44M
Q2 '252025-06-30$1.50M$-41.90M$-0.31$-33.90M
Q1 '252025-03-31$800.00K$-27.10M$-0.26$-19.70M
Q4 '242024-12-31$511.00K$-23.02M$-0.22$-12.25M
Q3 '242024-09-30$1.07M$-30.44M$-0.32$-22.46M
Q2 '242024-06-30$1.16M$-33.12M$-0.34$-35.07M
Q1 '242024-03-31$1.41M$-27.34M$-0.28$-34.69M
Q4 '232023-12-31$8.88M$-11.19M$2.49$-13.69M
Q3 '232023-09-30$2.37M$-16.74M$-0.85$-19.57M
Q2 2026 • period ending 2026-06-30 • filed 2026-07-16
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
17.70
P/S
565.82
EV/EBITDA
—
EV/Sales
530.98
ROE
-109.7%
ROA
-78.8%
Div Yield
0.00%
FCF Yield
-5.96%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.84B
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
1.12M
SI % of Float
1.79%
Days to Cover
3.94
Short Vol Ratio
42.8%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-26